Quantcast

Latest Drug Development Stories

2014-07-29 08:32:54

Phase I Project to Focus on Advanced Molecular Search Models for the Inverse Design Computational Drug Discovery Platform RESEARCH TRIANGLE PARK, N.C., July 29, 2014 /PRNewswire/ -- Cloud Pharmaceuticals, Inc., a therapeutics company focused on cloud-based drug design and development, announced today that it has been awarded a Phase I grant from the National Science Foundation Small Business Innovation Research (NSF SBIR) program. The grant is valued at $150,000. Cloud...

2014-07-29 08:30:24

BEVERLY HILLS, Calif., July 29, 2014 /PRNewswire/ -- Cannabis Capital Corp. (OTCBB: CBCA) is a global acquisition-based conglomerate targeting five primary industries: High-Tech Incubation, Drug Development, Entertainment/Media, Education, and Financial Services. The Editorial Board of the New York Times strongly voiced its opposition to current federal law on cannabis in its Sunday, July 27, 2014 publication writing, "the federal government should repeal the ban on marijuana.......

2014-07-24 16:27:29

BUENA, N.J., July 24, 2014 /PRNewswire/ -- IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based specialty generic drug development and manufacturing company, announced its financial results for the second quarter ended June 30, 2014. http://photos.prnewswire.com/prnvar/20130827/MM70487LOGO Second Quarter 2014 Highlights -- Total revenues of $6.5 million in the second quarter of 2014, an increase of 70% over the same quarter in 2013 -- Total revenues of $13.3 million...

2014-07-24 08:31:43

SAN DIEGO, July 24, 2014 /PRNewswire/ -- Cypher Genomics, Inc., the genome informatics company, announced today a co-promotion agreement with Illumina to facilitate the development of genomic-based biomarkers from whole genome sequence data for precision medicine and clinical trials. Cypher Genomics and Illumina will jointly offer pharmaceutical companies, through Illumina's sales force, a solution including Illumina's market leading sequencing technology, the NextBio platform for...

2014-07-23 23:13:54

Many current regenerative medicine trials are based on heterologous stem cell transplantation, in which stem cells multiplied from one type of organ or tissue are transferred to treat diseases, disorders, or injuries in a different type of organ or tissue. Boston’s Adult Stem Cell Technology Center, LLC (ASCTC) continues to develop technologies that could allow as well natural, homologous stem cell transplantation therapies for more human organs and tissues. Boston, MA (PRWEB) July 23,...

2014-07-21 23:06:38

GIA initiates research coverage on the global “Pediatric Drugs and Vaccines” market, as part of its ongoing multiple research projects on diverse industries and markets. The soon to be released report identifies rising incidence of metabolic conditions, cardiovascular and CNS diseases among children, rising per capita healthcare spends in emerging markets and a strong drug development pipeline, as primary growth drivers in the market. San Jose, California (PRWEB) July 21, 2014 Follow...

2014-07-21 08:29:00

LONDON, July 21, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Cell Culture Market by Equipment (Bioreactor, Incubator, Centrifuge), by Reagent (Media, Sera, Growth Factors, Serum Free Media), by Application (Cancer Research, Gene Therapy, Drug Development, Vaccine Production, Toxicity Testing) - Global Forecast to...

2014-07-16 12:28:25

Cognitive function is primary endpoint COPENHAGEN, Denmark, July 16, 2014 /PRNewswire/ -- Bracket is pleased to announce that Biotie Therapies, a specialized drug development company focusing on products for neurodegenerative and psychiatric disorders, has selected the CDR System for use as the primary endpoint for their phase 2 trial of SYN120, an orally administered, dual 5HT6/5HT2a antagonist. SYN120 is in development for the treatment of Parkinson's disease and other cognitive...

2014-07-14 23:04:05

Key Questions & Memorable Quotes from #eCongress Toronto, Canada (PRWEB) July 14, 2014 Throughout this past June 100s of mid-to-senior level executives from across the clinical trials space, representing 38 countries globally, registered for Xtalks 1st Annual eCongress webinar series entitled “Optimizing Patient Participation in Clinical Trials. Attract. Engage. Retain.” This well-attended eCongress kicked off with internationally renowned R&D expert, Ken Getz, of Tufts CSDD,...

2014-07-11 16:23:25

FALLS CHURCH, Va., July 11, 2014 /PRNewswire/ -- Poor bioavailability is a major reason for compounds to fail in preclinical development. Technology Catalysts International (TCI), a leading global pharmaceutical consulting firm, has compiled and analyzed technical and market information pertaining to the delivery of poorly water soluble or poorly permeable pharmaceutical compounds. Due to the complex nature of a multitude of existing as well as newly-discovered active ingredients,...


Word of the Day
holluschickie
  • A 'bachelor seal'; a young male seal which is prevented from mating by its herd's older males (mated bulls defending their territory).
This comes from the Russian word for 'bachelors.'
Related